Braveheart Bio, Inc. BRVE
18.60 USD +1.19 (+6.80%)
At closeNov 6, 2026, 4:00 PM EST
18.60 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
16.89 Day range 18.99
17.42 52-week range 30.00
- YTD
- -37.58%
- 1 year
- -37.58%
- Market cap
- 1.67B
- EPS (ttm)
- -6.08
- Shares out
- 90.04M
- Forward P/E
- -9.34
- YTD return
- -37.58%
- 1-year return
- -37.58%
- Volume
- 702.05K
- Avg volume
- 450.80K
- Open
- 17.55
- Previous close
- 17.42
- Day's range
- 16.89 – 18.99
- 52-week range
- 17.42 – 30.00
- Price target
- 45.25 (+143.3%)
- Earnings date
- Dec 8, 2026
5D -3.17 (-14.56%)
Key statistics
- Enterprise value
- 1.51B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 122.83M
- Total debt
- 575.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 22.91
- 200-day average
- 23.97
Analyst view
Price target (mean) 45.25 +143.3% upside
Now 18.60
- Target (low)
- 40.00
- Target (mean)
- 45.25
- Target (high)
- 48.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 8, 2026
Expected Dec 8, 2026. Consensus EPS estimate 0.00.
Financials — quick view
BRVE Revenue — quarterly 0
BRVE Net income — quarterly -14.99M
BRVE EPS — quarterly -2.51
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 8, 2026 | Sep 30, 2026 | -0.438 | — | — | — |
| Sep 8, 2026 | Jun 30, 2026 | 2.69 | -2.51 | -5.20 | -193.31% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- braveheart.bio
News
Braveheart Bio, Inc. (BRVE) Shareholder/Analyst Call Transcript 
Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial 
Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET 
Braveheart Bio Announces Late-breaking Presentation Of 52-Week Extension Data For BHB-1893 In Obstructive HCM At The American Heart Association Scientific Sessions, November 6-9; Will Also Host Webinar - Cantor Fitzgerald Reiterates Overweight on Braveheart Bio, Maintains $40 Price Target
- Braveheart Bio Q2 EPS $(2.51)
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48 
This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Cantor Fitzgerald Initiates Coverage On Braveheart Bio with Overweight Rating, Announces Price Target of $40
Your note
Sign in to keep a note on BRVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 6, 2026 | 0 |
| JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 6, 2026 | 7,420,090 |
| LUBNER DAVID CHARLES | Director | Purchase | Aug 6, 2026 | 55,555 |
| MURDOCH TRAVIS | Chief Executive Officer | Purchase | Aug 6, 2026 | 8,333,640 |
| RICKEY JAMES PAUL | Chief Financial Officer | Purchase | Aug 6, 2026 | 703,575 |
| VIEHBACHER CHRISTOPHER | Director | Purchase | Aug 6, 2026 | 759,857 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Leonard Rickey Investment Advisors P.L.L.C. | 0.04% | 36,109 | 670.90K | Sep 29, 2026 |
| SBI Securities Co., Ltd. | 0.00% | 10 | 185 | Sep 29, 2026 |
| Citigroup Inc. | 0.00% | 919 | 17.07K | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.52% | 2,273,151 | 42.24M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.15% | 1,035,862 | 19.25M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.87% | 779,600 | 14.48M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.80% | 718,200 | 13.34M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.62% | 559,564 | 10.40M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.56% | 500,000 | 9.29M | Sep 29, 2026 |